Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Depression is one of the most frequent and burdensome non-motor symptoms in
Parkinson's disease (PD), across all stages. Even when its severity is mild, PD depression …

Abstract Objective The Parkinson's Progression Markers Initiative (PPMI) is an
observational, international study designed to establish biomarker‐defined cohorts and …

Parkinson's disease varies widely in clinical manifestations, course of progression and
biomarker profiles from person to person. Identification of distinct Parkinson's disease …

Efforts to develop neuroprotective therapy for Parkinson disease (PD) are focusing on the
early stages of disease, which offer the best opportunity to intervene. Early PD can be …

Background Parkinson's disease is associated with an increased incidence of cognitive
impairment and dementia. Predicting who is at risk of cognitive decline early in the disease …

Parkinson's disease is highly heterogeneous in early clinical features and later outcomes.
This makes classifying subgroups of PD relevant to clinical research and practice …

Although Parkinson's disease (PD) is primarily a movement disorder, there are a range of
associated nonmotor symptoms, including cognitive impairment, depression and sleep …

Emerging concepts suggest that a multitude of pathology ranging from misfolding of alpha-
synuclein to neuroinflammation, mitochondrial dysfunction, and neurotransmitter driven …

The brain is a large-scale complex network whose workings rely on the interaction between
its various regions. In the past few years, the organization of the human brain network has …